These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21196202)

  • 81. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
    Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
    J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.
    Pievani A; Belussi C; Klein C; Rambaldi A; Golay J; Introna M
    Blood; 2011 Jan; 117(2):510-8. PubMed ID: 21048157
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
    Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
    Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Mechanism of action of rituximab.
    Cerny T; Borisch B; Introna M; Johnson P; Rose AL
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S3-10. PubMed ID: 12710585
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
    Lim SH; Vaughan AT; Ashton-Key M; Williams EL; Dixon SV; Chan HT; Beers SA; French RR; Cox KL; Davies AJ; Potter KN; Mockridge CI; Oscier DG; Johnson PW; Cragg MS; Glennie MJ
    Blood; 2011 Sep; 118(9):2530-40. PubMed ID: 21768293
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Rituximab: mechanism of action.
    Weiner GJ
    Semin Hematol; 2010 Apr; 47(2):115-23. PubMed ID: 20350658
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels.
    Nozaki Y; Mitsumori T; Yamamoto T; Kawashima I; Shobu Y; Hamanaka S; Nakajima K; Komatsu N; Kirito K
    Exp Hematol; 2013 Aug; 41(8):687-696.e1. PubMed ID: 23603515
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
    Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L; Wang DS; Lehman A; Chen CS; Johnson AJ; Marcucci G; Lee RJ; Lee LJ; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2008 Dec; 112(13):5180-9. PubMed ID: 18772452
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.
    Manzur S; Cohen S; Haimovich J; Hollander N
    Clin Exp Immunol; 2012 Dec; 170(3):291-9. PubMed ID: 23121670
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.
    Bil J; Winiarska M; Nowis D; Bojarczuk K; Dabrowska-Iwanicka A; Basak GW; Sułek K; Jakobisiak M; Golab J
    Blood; 2010 May; 115(18):3745-55. PubMed ID: 20200358
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.
    Martinez-Paniagua MA; Vega MI; Huerta-Yepez S; Baritaki S; Vega GG; Hariharan K; Bonavida B
    Mol Cancer Ther; 2012 Mar; 11(3):572-81. PubMed ID: 22267549
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
    Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
    [TBL] [Abstract][Full Text] [Related]  

  • 93. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Complement activation determines the therapeutic activity of rituximab in vivo.
    Di Gaetano N; Cittera E; Nota R; Vecchi A; Grieco V; Scanziani E; Botto M; Introna M; Golay J
    J Immunol; 2003 Aug; 171(3):1581-7. PubMed ID: 12874252
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
    Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
    [TBL] [Abstract][Full Text] [Related]  

  • 97. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
    van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
    Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
    Jeon MJ; Yu ES; Choi CW; Kim DS
    Korean J Intern Med; 2023 Nov; 38(6):893-902. PubMed ID: 37599392
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.
    Panjideh H; Niesler N; Weng A; Fuchs H
    Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878216
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
    Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
    BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.